About

Mighty Capital is a Silicon Valley venture capital firm that invests in companies building “products that count:” products that transform lives and create value at scale.
  • Portfolio companies say that we bring the “best value for the dollar invested”
    • We co-invest with top VCs at later stage
    • We are committed to being the most helpful investor you will ever have
  • The unique value we bring to our portfolio is:
    • The combination of handpicked Silicon Valley investors, and
    • Proprietary access to one of the largest networks of product managers in the world (>200,000 product managers), which can become hires, customers, and more
Our investment criteria are:
  • Demonstrated evidence of product/market fit,
  • Amazing CEO and Bay-Area-based leadership,
  • Not the first money in –previous funding or revenue traction.
If you or someone you know runs a company that meets those criteria, we’d love to hear about it! The best way to get in touch with us is via a mutual connection, most likely a current investor or your law firm. If that’s not an option, then email dealflow@mighty.capital.

Blog


September 4, 2017

A killer pitch deck sounds like a story by design. It is meant to help you step back from the details of your business or new product, to tell a compelling story to an investor. It reads as simple as this: “We are a unique team, excited to solve a big and hard problem. We came up with a sustainably differentiated solution. As a result, we are gaining solid traction, which we monetize fairly. So our financials look extremely promising but to get there, we need a reasonable amount of funding. We have a credible plan to generate significant returns for our investors.”

Read More

February 3, 2017

When a due diligence is appropriate, we ask the entrepreneur to make a data room available to the due diligence team. Through a review of the material in the data room and discussions with the CEO, exec team and references, the due diligence lead is able to cover the key aspects of the due diligence: team, business, financing, and match with Mighty Capital.

Read More

December 14, 2018

Mission Bio delivers targeted single-cell genomics solutions for high-impact applications with Tapestri, the Precision Genomics Platform. Tapestri is the industry’s first targeted single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables, and analysis software, which integrate seamlessly with existing NGS workflows. With Tapestri, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.

Read More

December 11, 2018

In this interview with The Full Ratchet, SC Moatti talks about 13 quick takeaways; including SC’s 3 rules of the most successful products. Explains that “Mobilized” shares examples and case studies implementing those rules.

Read More

November 19, 2018

Raising a Series A is a huge accomplishment and closing it might feel like you’ve crossed the finish line but the pressure only goes up from here.

Read More

November 8, 2018

Startups working with leading edge technology know that hiring for the most in-demand skills comes with a cost — not just in salary but also in equity grant amounts. The right insight makes reaching your funding goals easier.

Read More

November 6, 2018

We had a lot of fun at our holiday party and are grateful to the investors, entrepreneurs and friends who were able to join us. This is a brief video capturing the vibe of the event.

Read More

October 22, 2018

When VPs, Directors and Managers sit down to negotiate offer terms, there’s a huge gap between West and East Coast outcomes. In Silicon Valley, candidates command 3-4 times the value in new hire grants compared to those out east. Why the difference, and how should startups position themselves accordingly?

Read More

October 17, 2018

Mighty Capital is hiring an exceptional individual to join us as an AssociatePrincipal and have a direct impact our organization. They will be responsible for managing the deal flow, performing analysis, coordinating partner and volunteer activities, and taking on other ad-hoc tasks. Strong interpersonal skills, strategic thinking with exceptional analytical and presentation skills, high energy and a service mindset approach are a must. To apply: email you cover letter and resume to sc@mighty.capital with the title “Candidate for the Associate/Principal position: <your name>”

Read More

September 25, 2018

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced a first-of-its-kind study demonstrating its ability to perform single-cell DNA analysis at speed and scale orders of magnitude higher than prior methods. The study, published in Genome Research and co-authored by researchers at Mission Bio and MD Anderson Cancer Center, illustrates its Tapestri platform’s ability to identify the evolution of cellular mutations in Acute Myeloid Leukemia (AML) tumors. This study provides unprecedented insight into the cells that drive complex diseases like cancer and opens the door to the routine sequencing of tumors.

Read More

September 25, 2018

Who pays higher salaries for data scientists — Google or emerging startups in Silicon Valley? You might think it’s a silly question, but if you answered Google, you’d be wrong. For founders, skilled worker base compensation is no longer a cost cutting haven.

Read More

August 8, 2018

In this article commissioned by Business Insider, Melia Robinson examines how venture capital firms are specializing in order to compete for hot investment deals. This article includes Mighty Capital as an example of this trend and also re-shares quotes from Managing Partner, SC Moatti’s previous interview and 7/17/2018 Business Insider article also written by Melia Robinson.

Read More

© 2018 Mighty Capital All Rights Reserved